Nasdaq

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules

Data Reinforce the Clinically Meaningful Impact of INGREZZA in Adults with Huntington's Disease Chorea Findings Presented at the 2025 American Association of Neuroscience Nurses Neuroscience Advanced ...

Neurocrine Biosciences Presents New Clinically Meaningful Response Data On Treatment Of Tardive Dyskinesia, Reinforcing The Efficacy Of INGREZZA® (Valbenazine) Capsules Across ...

Neurocrine Biosciences Presents New Clinically Meaningful Response Data On Treatment Of Tardive Dyskinesia, Reinforcing The Efficacy Of INGREZZA® (Valbenazine) Capsules Across A Broad Range Of ...
Seeking Alpha

Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically ...

SAN DIEGO, Feb. 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today announced top-line data from a Phase 4 study, KINECT-PRO™, demonstrating clinically meaningful and ...
NBC4 Columbus

Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022

SAN DIEGO, Nov. 3, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a leading neuroscience-focused biopharmaceutical company, today reported additional results from the Phase 3 KINECT ...
Seeking Alpha

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules

SAN DIEGO, March 17, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) presented data from the KINECT ®-HD study showcasing significant improvements in chorea across body regions ...